Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Dyslipidemias

This is a "connection" page, showing publications Michael H. Davidson has written about Dyslipidemias.

 
Connection Strength
 
 
 
14.915
 
  1. Pulipati VP, Davidson MH. How I treat statin-associated side effects in an outpatient setting. Future Cardiol. 2021 10; 17(7):1249-1260.
    View in: PubMed
    Score: 0.763
  2. Pulipati VP, Davidson MH. Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
    View in: PubMed
    Score: 0.742
  3. Benes LB, Brandt DJ, Brandt EJ, Davidson MH. How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. Curr Cardiol Rep. 2018 10 17; 20(12):138.
    View in: PubMed
    Score: 0.653
  4. Brandt EJ, Benes LB, Lee L, Dayspring TD, Sorrentino M, Davidson M. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. J Cardiovasc Pharmacol Ther. 2019 01; 24(1):54-61.
    View in: PubMed
    Score: 0.639
  5. Benes LB, Bassi NS, Kalot MA, Davidson MH. Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. Cardiol Clin. 2018 May; 36(2):277-285.
    View in: PubMed
    Score: 0.624
  6. Robinson JG, Davidson MH. Can We Cure Atherosclerosis? Rev Cardiovasc Med. 2018; 19(S1):S20-S24.
    View in: PubMed
    Score: 0.618
  7. Roth EM, Davidson MH. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. Rev Cardiovasc Med. 2018; 19(S1):S31-S46.
    View in: PubMed
    Score: 0.618
  8. Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
    View in: PubMed
    Score: 0.534
  9. Davidson MH. Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. EBioMedicine. 2015 Apr; 2(4):284.
    View in: PubMed
    Score: 0.508
  10. Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
    View in: PubMed
    Score: 0.478
  11. Davidson MH, Rooney M, Pollock E, Drucker J, Choy Y. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013 Sep-Oct; 7(5):423-32.
    View in: PubMed
    Score: 0.450
  12. Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.424
  13. Davidson MH. Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
    View in: PubMed
    Score: 0.396
  14. Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.353
  15. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
    View in: PubMed
    Score: 0.330
  16. Davidson MH, Ballantyne CM. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. Am J Cardiol. 2008 Apr 17; 101(8A):1B-2B.
    View in: PubMed
    Score: 0.315
  17. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
    View in: PubMed
    Score: 0.315
  18. Polonsky TS, Davidson MH. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.315
  19. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008; 8(2):69-81.
    View in: PubMed
    Score: 0.309
  20. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007 Oct; 8(15):2569-78.
    View in: PubMed
    Score: 0.304
  21. Davidson MH. Squalene synthase inhibition: a novel target for the management of dyslipidemia. Curr Atheroscler Rep. 2007 Jan; 9(1):78-80.
    View in: PubMed
    Score: 0.288
  22. Davidson MH. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
    View in: PubMed
    Score: 0.288
  23. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
    View in: PubMed
    Score: 0.287
  24. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006 Aug 21; 98(4A):27i-33i.
    View in: PubMed
    Score: 0.276
  25. Clark LT, Maki KC, Galant R, Maron DJ, Pearson TA, Davidson MH. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med. 2006 Apr; 21(4):320-6.
    View in: PubMed
    Score: 0.274
  26. Deedwania PC, Maki KC, Dicklin MR, Stone NJ, Ballantyne CM, Davidson MH. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
    View in: PubMed
    Score: 0.269
  27. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
    View in: PubMed
    Score: 0.265
  28. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
    View in: PubMed
    Score: 0.263
  29. Toth PP, Davidson MH. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005 Jan; 6(1):131-9.
    View in: PubMed
    Score: 0.251
  30. Davidson M. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Prev Cardiol. 2005; 8(4):244-9.
    View in: PubMed
    Score: 0.251
  31. Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.187
  32. Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
    View in: PubMed
    Score: 0.172
  33. Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
    View in: PubMed
    Score: 0.171
  34. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.147
  35. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
    View in: PubMed
    Score: 0.145
  36. Davidson MH, Benes LB. The future of n-3 polyunsaturated fatty acid therapy. Curr Opin Lipidol. 2016 12; 27(6):570-578.
    View in: PubMed
    Score: 0.143
  37. Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 01; 36(8):1211-22.
    View in: PubMed
    Score: 0.121
  38. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
    View in: PubMed
    Score: 0.116
  39. Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
    View in: PubMed
    Score: 0.104
  40. Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
    View in: PubMed
    Score: 0.103
  41. Stalenhoef AF, Davidson MH, Robinson JG, Burgess T, Duttlinger-Maddux R, Kallend D, Goldberg AC, Bays H. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
    View in: PubMed
    Score: 0.101
  42. Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.098
  43. Brown WV, Bays H, Davidson M, Goldberg A. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 Mar-Apr; 5(2):66-75.
    View in: PubMed
    Score: 0.096
  44. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
    View in: PubMed
    Score: 0.089
  45. Davidson MH. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
    View in: PubMed
    Score: 0.087
  46. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.086
  47. Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, Sisk CM, Mitchel YB. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov; 26(4):547-60.
    View in: PubMed
    Score: 0.082
  48. Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May; 204(1):208-15.
    View in: PubMed
    Score: 0.081
  49. Davidson MH, Jones PH. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008; 28(10):615-23.
    View in: PubMed
    Score: 0.077
  50. Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34.
    View in: PubMed
    Score: 0.077
  51. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J. 2006 Nov; 152(5):976-81.
    View in: PubMed
    Score: 0.071
  52. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
    View in: PubMed
    Score: 0.069
  53. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015 Jun; 14(6):935-55.
    View in: PubMed
    Score: 0.032
  54. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May; 53(5):741-50.
    View in: PubMed
    Score: 0.021
  55. Kawata AK, Revicki DA, Thakkar R, Jiang P, Krause S, Davidson MH, Punzi HA, Padley RJ. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009; 29(4):215-29.
    View in: PubMed
    Score: 0.021
  56. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.